The 2008 Canadian Hypertension Education Program recommendations: The scientific summary - An annual update

Canadian Journal of Cardiology

Volumn 24, Issue 6, 2008, Pages 447-452

  Campbell, Norman ^a  

^a LIBIN CARDIOVASCULAR INSTITUTE OF ALBERTA   (Canada)

Author keywords

Clinical practice guidelines; High blood pressure; Hypertension; Knowledge translation

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE PLUS PERINDOPRIL; LOOP DIURETIC AGENT; PLACEBO; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ADD ON THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CANADA; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG INDICATION; EVIDENCE BASED MEDICINE; HEALTH EDUCATION; HIGH RISK POPULATION; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MICROALBUMINURIA; PATIENT COMPLIANCE; PATIENT EDUCATION; PRACTICE GUIDELINE; RISK REDUCTION; SODIUM RESTRICTION; TREATMENT CONTRAINDICATION; WHITE COAT HYPERTENSION; CLINICAL COMPETENCE; HEALTH CARE QUALITY; MEDICAL EDUCATION; REVIEW; STANDARD;

ANTIHYPERTENSIVE AGENTS; CANADA; CLINICAL COMPETENCE; EDUCATION, MEDICAL, CONTINUING; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC; PROGRAM EVALUATION;

EID: 46249121332     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(08)70618-4     Document Type: Article

References (24)

1. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet 2006;368:1449-56. (Erratum in 2006;368:2124).
2. Smith ER. The Canadian Heart Health Strategy and action plan. Can J Cardiol 2007;23:399-400.
3. Patel A; ADVANCE Collaborative Group, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet. 2007;370:829-40.
4. Montague TJ, Gogovor A, Krelenbaum M. Time for chronic disease care and management. Can J Cardiol 2007;23:971-5.
5. Cappuccio FP, Kerry SM, Forbes L, Donald A. Blood pressure control by home monitoring: Meta-analysis of randomised trials. BMJ 2004;329:145-50. (Erratum in 2004;329:499).
6. McKay DW, Godwin M, Chockalingam A. Practical advice for home blood pressure measurement. Can J Cardiol 2007;23:577-80.
7. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41. (Errata in 2001;358:1556, 2002;359:2120).
8. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967;202:1028-34.
9. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970;213:1143-52.
10. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. BMJ 2003;326:1427-34.
11. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97. (Errata in 2003;289:178, 2004;291:2196).
12. Lithell H, Hansson L, Skoog I, et al; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-86.
13. Lindholm LH, Ibsen H, Dahlöf B, et al; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002;359:1004-10.
14. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: A network meta-analysis. Lancet 2007;369:201-7. (Erratum in 2007;369:1518).
15. Phillips RA. New-onset diabetes mellitus less deadly than elevated blood pressure? Following the evidence in the administration of thiazide diuretics. Arch Intern Med 2006;166:2174-6.
16. Mason JM, Dickinson HO, Nicolson DJ, Campbell F, Ford GA, Williams B. The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension. J Hypertens 2005;23:1777-81.
17. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes 2003;27:S1-S152.
18. Padwal RS, Hemmelgarn BR, McAlister FA, et al; Canadian Hypertension Education Program. The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 - blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2007;23:529-38.
19. Khan NA, Hemmelgam BR, Padwal R, et al; Canadian Hypertension Education Program. The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 - therapy. Can J Cardiol 2007;23:539-50.
20. Onysko J, Maxwell C, Eliasziw M, Zhang JX, Johansen H, Campbell NR; Canadian Hypertension Education Program. Large increases in hypertension diagnosis and treatment in Canada after a healthcare professional education program. Hypertension 2006;48:853-60.
21. Neutel CI, Campbell NR. Antihypertensive medication use by recently diagnosed hypertensive Canadians. Can J Cardiol 2007;23:561-5.
22. Campbell NR, Onysko J, Johansen H, Gao RN. Changes in cardiovascular deaths and hospitalization in Canada. Can J Cardiol 2006;22:425-7.
23. Campbell NR, Tu K, Brant R, Duong-Hua M, McAlister FA; Canadian Hypertension Education Program Outcomes Research Task Force. The impact of the Canadian Hypertension Education Program on antihypertensive prescribing trends. Hypertension 2006;47:22-8.
24. Campbell NR, Petrella R, Kaczorowski J. Public education on hypertension: A new initiative to improve the prevention, treatment and control of hypertension in Canada. Can J Cardiol 2006;22:599-603.